SLC5A2 and hydrops fetalis: Among 12,251 persons participating in the DELIVER and EMPEROR-Preserved trials, SGLT2 inhibitors lowered the composite endpoint of CV or first hospitalization for HF (HR 0.80) with consistent decreases in both the components of CV mortality (HR 0.88) and the first hospitalization for HF (HR 0.74) [76].